SKUDEXUM 75 mg/25 mg, dexketoprofen/tramadol, Fixed NSAID-weak opioid combination

PAIN - New medicinal product

Opinions on drugs - Posted on Jul 20 2016

Inclusion

SKUDEXUM has Marketing Authorisation in the short-term symptomatic treatment of moderate to severe acute pain in adult patients whose pain requires a combination of tramadol and dexketoprofen.
Its analgesic superiority relative to each of its constituents administered as a monotherapy was demonstrated in two studies.
No comparison with other fixed analgesic combinations is available.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account